Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...
The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks ... The company plans to submit a supplementary biologics license application for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback